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A 57-year-old man with a medical history signiﬁcant for bipolar disorder, depression, and
anxiety presented in 2010 with bilateral lower extremity numbness progressing to perineal
numbness and urinary retention. A “working” diagnosis of relapsing-remitting MS (RRMS) was
supported by disseminated T2 hyperintensities on MRI investigations of the brain and spinal
cord. Furthermore, CSF analysis revealed 4 unique oligoclonal bands not identiﬁed in blood.
Initial treatment with IM interferon beta-1a exacerbated the patient’s depression, prompting
discontinuation after only 6 weeks of injection therapy. He was then transitioned to daily
subcutaneous glatiramer acetate, which was well tolerated and resulted in disease stabilization
for approximately 12 months. He had a relapse in 2011 with symptoms corresponding to a new
enhancing lesion in the thoracic spinal cord.
The pronounced MS disease burden in the spinal cord, in conjunction with breakthrough
disease activity while on glatiramer acetate, prompted the treating team to recommend intensiﬁcation of disease-modifying therapy with natalizumab, which was administered IV every 4
weeks from 2011 to 2014 for a total of 33 treatments. He had no evidence of disease activity
during this time. While on natalizumab, he was monitored for the presence of John Cunningham virus (JCV) antibodies, as it is known that natalizumab treatment in MS confers a high
risk to develop progressive multifocal leukoencephalopathy (PML) in patients with a high JCV
index. In March 2014, a positive JCV IgG was identiﬁed in conjunction with an (elevated) index
of 1.77. To mitigate the risk of PML, extended interval dosing (EID) of every ;6 weeks was
instituted, and he received an additional 32 treatments through January 2018 (65 total infusions
over the course of 7 years).
In mid-January 2018, the patient began exhibiting slurred speech. One week later, he was unable
to stand independently. Despite the absence of any new lesions identiﬁed on MRI, the likelihood of a new MS exacerbation was considered suﬃciently compelling to commence daily
treatment with 1,000 mg of IV methylprednisolone for a total of 6 days. Despite the absence of
any objective clinical improvement, he was discharged to a rehabilitation center. Subsequently,
suspicion of PML prompted urgent transfer to our center for further evaluation.
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On clinical examination, his mental status and cranial nerve
examinations were normal, including intact extraocular eye
movements. Motor examination was notable for mild weakness in the right hip and knee ﬂexors, without associated
sensory deﬁcits. His reﬂexes were brisk and symmetric in the
upper extremities, 3+ at the right patella and ankle, 2+
throughout the left lower extremity, with an equivocal right
ﬂexor, and left plantar response, respectively. He exhibited
scanning dysarthria, left greater than right dysdiadochokinesia, and ataxia in both upper and lower extremities.
An MRI obtained at admission was notable for a small
punctate new enhancing lesion in the right cerebellar white
matter (ﬁgure, A). The few scattered supratentorial chronic
demyelinating lesions did not enhance with contrast. The
MRI investigations from his initial assessment in another
center were not available to us for comparison. A lumbar
puncture revealed opening pressure of 18 mm Hg with zero
white or red blood cells in the CSF with protein of 50 mg/dL
and glucose of 67 mg/dL. A JCV PCR was sent, but results
were not immediately available.

Diﬀerential diagnosis
The most salient feature in the patient’s presentation, and that
which compelled a broad diﬀerential diagnostic exploration,
was the severe and neurologically disabling cerebellar syndrome, without evidence of concomitant and commensurate
neuroradiologic correlates of disease activity.
Certain medications may cause cerebellar toxicity, including antiepileptic agents and chemotherapeutic agents.
Lithium toxicity is characterized by rapid postural and action tremor, encephalopathy, dysarthria, ataxia, and nystagmus.1 Of relevance was the fact that our patient had been
on lithium for decades, although his serum lithium level was
normal: 0.8 mmol/L (reference range 0.6–1.2 mmol/L).
Deﬁciencies, including thiamine, B12, vitamin E, or copper
(especially in the context of zinc excess), can cause subacute progressive cerebellar ataxias. Our patient had no
known predisposing risk factors, and extensive testing
failed to demonstrate any evidence of toxicity or of a deﬁciency state.

Figure A 57-year-old man with relapsing-remitting MS (RRMS) and new-onset ataxia

Axial fluid-attenuated inversion recovery (FLAIR) image of the posterior fossa (A) from March 2018 showed a new punctate enhancing lesion in the right
cerebellar deep white matter (green arrow), which was disproportionate to the clinical cerebellar syndrome. September 2017 axial (B) and sagittal (C) FLAIR
images compared with March 2018 axial (D) and sagittal (E) FLAIR images showed interval development of asymmetrical pathologic cerebellar atrophy with
widened sulci (yellow arrows). Patchy cortical FLAIR hyperintensities were also observed in the cerebellar folia (purple arrow). (F–H) Coronal post-contrast T1weighted images of the cerebellar hemisphere performed at 1-month intervals during the 2018 admission showed development of leptomeningeal and
parenchymal enhancement (blue arrows) following withdrawal of natalizumab and after plasma exchange treatment suggestive of immune reconstitution
inflammatory syndrome (IRIS). Partial resolution of the enhancement was also demonstrated subsequently following steroid therapy.
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Infectious causes were broadly considered; in particular, for
those with known predilection for aﬀecting the cerebellum or
its networks. The patient is not in the typical age group for the
development of postinfectious cerebellitis, a condition considerably more common in children and young adults and
predominantly in association with varicella, measles, or
Epstein-Barr virus infections.2 Brainstem encephalitis with
predominant cerebellar signs can be seen with enterovirus
A71 and listeria infections. Although these are conditions
where CSF and MRI investigations would be expected to
commonly reveal signs of inﬂammation, the concomitant
treatment with immunotherapy, especially with those capable
of producing immune suppression (including natalizumab),
could compromise surveillance mechanisms that usually recognize and neutralize such infectious challenges.
Other immune-mediated mechanisms including paraneoplastic cerebellar degeneration (anti-Yo, anti-Hu, anti-Ri, or
anti-Ma) are associated with severe Purkinje cell damage and
can present with normal MRI ﬁndings early in the disease
process.3 Glutamic acid decarboxylase antibody–associated
ataxia can also fail to reveal remarkable ﬁndings on MRI at
initial stages of the disease.4
Recrudescence of RRMS in the setting of EID was considered,
but clinical and radiographic evidence of disease activity can
be expected to rebound starting around 12–16 weeks following the cessation of natalizumab treatment,5 whereas our
patient was being treated every ;6 weeks.

In the setting of prolonged natalizumab exposure and JCV
titer >1.5, PML must be the cardinal diagnostic consideration
in a patient with RRMS manifesting new neurologic symptoms or exhibiting interval changes on surveillance imaging
investigations (table).6

Final diagnosis
MRI studies acquired from September 2017 were ﬁnally
obtained (ﬁgure, B and C), revealing signiﬁcant and asymmetric
interval worsening of cerebellar atrophy, as evidenced by the
prominent and diﬀuse widening of the cerebellar sulci (ﬁgure, D
and E). The ﬂuid-attenuated inversion recovery sequence
revealed a patchy hyperintensiﬁcation, discretely localized to the
parenchyma (ﬁgure, D and E), and mild restricted diﬀusion in
addition to the punctate enhancement within the right cerebellar deep white matter. Taken together, the interval MRI
ﬁndings raised the possibility of granule cell neuronopathy
(GCN), a JCV infection of the granule cells of the cerebellum.
PCR testing (Mayo) of the CSF for JCV returned positive with
3,931 copies/mL (Quest) supporting the diagnosis.

Final clinical disposition
The patient subsequently developed horizontal nystagmus
with saccadic intrusions and spontaneous intermittent left
lower extremity ﬂexing in a pattern suggestive of myoclonus.
Natalizumab was discontinued, and he was treated with 3

Table Diagnostic and treatment considerations in breakthrough disease activity in patients with MS treated with
natalizumab
Differential diagnostic
considerations (in order of urgency)

Clinical
characteristics

Progressive multifocal
leukoencephalopathy (PML)

MRI features

Suggested intervention(s)

Retrochiasmal
visual syndromes

Lesions of broad heterogeneity,
T1 hypointensity, and GAD
enhancement in up to 30%–40%.

1. Stop natalizumab

Language
disorders

Confluent lesions extending into
the “U” fibers

2. Plasma exchange to remove natalizumab (3–5
exchanges).

Stroke-like
syndromes

At early stages, imaging may be
normal.

3. IVIg either instead of plasma exchange (anti-idiotypic
blocking) or after plasma exchange (remove cytokines
and other immune mediators)

Myoclonus/
seizures

4. Steroids, e.g., 1 g IV methylprednisolone weekly × 12
weeks; then every other week for 6 doses; then
monthly for 3 doses.

Natalizumab neutralizing
antibodies (in most cases, they
develop after 12–24 weeks of
treatment)

Indistinguishable
from MS
exacerbations

Indistinguishable from MS
lesions

Treat as an MS exacerbation, then transition to new MS
disease-modifying therapy.

True breakthrough MS exacerbation
despite adherent therapy and
absence of neutralizing antibody

Indistinguishable
from MS
exacerbations

Indistinguishable from MS
lesions

Treat as an MS exacerbation. Continue therapy in
conjunction with clinically and MRI surveillance to
ensure stability. Also can consider transition to new MS
disease-modifying therapy.

Alternative diagnosis concomitant
with MS (e.g., drug toxicity,
infection, deficiency states, and
trauma)

Depend on the
etiology of the
disorder

Depend on the etiology of the
disorder

Contingent on diagnostic entity and its confirmation.

Neurology.org/NN

Neurology: Neuroimmunology & Neuroinflammation | Volume 6, Number 3 | May 2019

3

cycles of plasma exchange. MRI showed evidence of inﬂammatory reconstitution immune syndrome (IRIS) in the
form of new leptomeningeal and parenchymal enhancement
in the cerebellar hemispheres (ﬁgure, G).
The patient was treated with IV methylprednisolone 1,000 mg
daily for 3 days after which imaging showed improvement in
the pattern of enhancement (ﬁgure, H). Intermittent autonomic instability led to posterior reversible encephalopathy
syndrome, which improved radiographically, although the
patient’s mental status declined. Ultimately, he became unresponsive without brainstem reﬂexes. Sedating medications
were weaned with prompt return of abnormal lower extremity
movements, although there was no improvement in level of
consciousness. Electroencephalography showed no evidence
of seizure activity. He underwent a cerebral cortex biopsy to
rule out alternative explanations for his level of consciousness
including CD8-encephalitis and PML, but the biopsy revealed
histologically normal brain tissue. Serial CSF analysis showed
31 copies/mL of JCV by June 2018, but the patient demonstrated no indication of awareness of self or environmental
surroundings. He was transitioned to comfort care and died
approximately 7 months after symptom onset. Postmortem
examination was not performed.

Discussion
Cerebellar granule cell layer pathology in the setting of JCV
infection was ﬁrst described in 1983 in 5% of patients having
PML.7 In 1993, large hypochromatic nuclei were described in
the granule cell layer of patients with HIV and PML without any
evidence of JCV or HIV DNA within those cells.8 However, in
2003, a patient with HIV with PML and cerebellar atrophy was
found to have JCV isolated in the granule cell neurons, suggesting that pathologic changes were related to a JCV infection.9
In 2005, a patient with HIV presented with cerebellar syndrome
and pathologic ﬁndings consistent with GCN without a coexisting PML appearing infection10 revealing GCN as a unique
clinical JCV-mediated syndrome distinct from PML.
There have been 4 cases of natalizumab-associated GCN
published in the literature since 2013.11–14 Three patients11–13
were treated with plasma exchange (3 or 5 treatments), 2 of
whom developed subsequent IRIS. All patients survived with
signiﬁcant morbidity, and the Expanded Disability Status Scale
score on follow-up for each of them was 7.0. The fourth patient14 was treated with granulocyte colony-stimulating factor 3
months after her ﬁnal treatment with natalizumab and is the
only patient in this series to improve despite complications
from IRIS. Her Expanded Disability Status Scale score was 8.0
at the nadir and improved to 6.5 three months after treatment.
Histologically, in GCN, patients demonstrate loss of the
granule cell layer of the cerebellum, with increased CD68 +
macrophages/microglia, perivascular cuﬀs containing predominantly CD20+ B cells with diﬀuse of inﬁltration of CD8+
4

T cells that produce interferon γ.11,12 Mutations in the
C-terminus of the VP1 capsid gene of JCV are believed to
make this virus tropic to the granule cell.12
Evidence suggests that eﬃcacy of natalizumab is not reduced
with interval dosing up to 8 weeks.15 Furthermore, the risk of
PML decreases signiﬁcantly with EID compared with standard dosing intervals in patients with prolonged exposure to
natalizumab.16 Although EID may reduce the risk of PML, it
does not eliminate it. Furthermore, although there have been
cases of EID-associated PML, our case represents the ﬁrst
known case of GCN in a patient on EID of natalizumab.
There are no controlled studies or guidelines for treatment
of GCN and no antiviral drugs that are eﬀective against JCV.
In patients with PML in the setting of natalizumab therapy,
plasma exchange is often used to remove the natalizumab,
but this treatment is often associated with fulminant CNS
inﬂammation as the immune cells target the PML lesions.
Although the immune response is critical for controlling the
infection, the inﬂammation (i.e., IRIS) can damage the
surrounding brain parenchyma. To prevent the damage
caused by inﬂammation, corticosteroids are used to temper
the immune response, albeit protracted regimens may be
necessary to control the process of IRIS (table). This case
illustrates the challenges posed in the diagnosis and management of patients with PML in general and for the GCN
variant in particular.
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